PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 608 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 Got the COVID Blues? August 12, 2020 EMA Recommends Extension of Indications for Atezolizumab September 28, 2020 20 years of Cancer Research UK: Celebrating our research nurses December 7, 2022 Load more HOT NEWS Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer Community Surprises Teen Battling Bone Cancer With Brand New Car For... BooHoo Is Selling Bras With Subtle Patterns To Help You Check... Breast Cancer Survivor Driven from Her Home by Noxious Gases from...
